Analyst Consensus ?
ConsensusBuy27 ratings
Bullish2488.9%
Neutral311.1%
Bearish00.0%
Kymera Therapeutics, Inc. · KYMR · FY2025 Q3 · Calendar Q4 2025
Kymera advances KT-621 trials; patient efficacy remains the key test
The quarter's investment case rests on whether Kymera can translate early KT-621 progress into convincing patient outcomes. Pipeline execution and a substantial cash runway support continued development, but clinical efficacy is not yet established in the supplied analysis.
Reported Before market openNASDAQHealthcare
$10.81B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$-0.90
Consensus $-0.71
EPS surprise
-26.8%
Reported versus consensus
Reported revenue
$2.8M
Consensus $14.5M
Revenue surprise
-80.9%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+0.3%
Event window
SPY move
-1.2%
Same window
Abnormal move
+1.5%
Stock minus SPY
Volume
1.3×
Versus trailing sessions
Subsequent drift
+10.1%
Up to 20 sessions
KYMRSPY benchmark
Ask FN2 about KYMR FY2025 Q3
Transcript, numbers and history already loaded
Why did KYMR rise 0.3% after missing EPS estimates in FY2025 Q3?What changed in KYMR's guidance and outlook in FY2025 Q3?Give me the bull and bear case for KYMR after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The call analysis describes Phase Ib work for KT-621 as completed and Phase IIb atopic dermatitis and asthma trials as underway. It also highlights KT-579 moving toward Phase I and the Gilead CDK2 collaboration. Compared with the prior-quarter analysis, the stated emphasis has shifted from planned milestones toward ongoing trials and the upcoming Phase Ib data readout; these are management plans and progress updates, not proof of clinical benefit.
Guidance delta
Guidance sentiment was maintained. The supplied analysis does not identify a new numeric financial outlook; focus remains on trial progression and planned data milestones.
Key takeaways
- KT-621 is advancing in atopic dermatitis and asthma, but patient efficacy and differentiation from existing options remain unproven.
- The analysis points to a December 2025 Phase Ib readout and mid-2027 Phase IIb atopic dermatitis results as milestones management identified.
- KT-579 is moving toward a Phase I healthy-volunteer study; the Gilead collaboration extends the pipeline into oncology.
- Cash and collaboration support were cited as resources for development, while clinical and partnership uncertainties remain.
Management priorities
- Advance KT-621 studies in atopic dermatitis and asthma and deliver planned clinical readouts.
- Move KT-579 toward its planned Phase I study and progress the Gilead CDK2 program.
- Use collaboration milestones and the stated cash runway to support pipeline development.
Follow KYMR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$126.63Previous close
$32Low
$109.4Average
$180High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Nov 2, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Buy | Buy | Maintain | Oct 30, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 30, 2026 |
| BTIG | Buy | Buy | Maintain | Oct 29, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 27, 2026 |
| Citigroup | Buy | Buy | Maintain | Oct 5, 2026 |
| Stifel | Buy | Buy | Maintain | Sep 22, 2026 |
| B of A Securities | Buy | Buy | Maintain | Sep 14, 2026 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Sep 10, 2026 |
| Guggenheim | Buy | Buy | Maintain | Aug 31, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 27, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 16, 2026 |
| B. Riley Securities | Buy | Buy | Maintain | Jun 29, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Jun 26, 2026 |
| UBS | Buy | Buy | Maintain | Mar 3, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | Mar 2, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Feb 26, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Dec 10, 2025 |
| Oppenheimer | Outperform | Outperform | Maintain | Dec 9, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Dec 9, 2025 |
| Jefferies | Buy | Buy | Maintain | Dec 9, 2025 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Dec 9, 2025 |
| Credit Suisse | Neutral | Neutral | Maintain | Aug 4, 2023 |
| Raymond James | Outperform | Market Perform | Upgrade | May 5, 2023 |
| Goldman Sachs | Buy | Buy | Maintain | Dec 16, 2022 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Dec 15, 2022 |
| Berenberg | Buy | Buy | Maintain | Apr 14, 2021 |
Named analyst price targets
Upside is calculated against the persisted previous close $126.63. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Oppenheimer | Jeff Jones | $140 | $122.6 | +10.6% | Oct 29, 2026 |
| Loop Capital Markets | Leah Rush Cann | $132 | $121.52 | +4.2% | Oct 29, 2026 |
| Raymond James | Thomas Deal | $140 | $109.3 | +10.6% | Oct 8, 2026 |
| Piper Sandler | Biren Amin | $140 | $119.9 | +10.6% | Sep 23, 2026 |
| Stifel Nicolaus | Analyst unavailable | $152 | $117.67 | +20.0% | Sep 22, 2026 |
| Wolfe Research | Analyst unavailable | $180 | $115.43 | +42.1% | Sep 10, 2026 |
| Guggenheim | Brad Canino | $170 | $118.15 | +34.2% | Aug 31, 2026 |
| Morgan Stanley | Judah Frommer | $135 | $104.96 | +6.6% | Aug 6, 2026 |
| Barclays | Analyst unavailable | $139 | $105.48 | +9.8% | Aug 6, 2026 |
| Oppenheimer | Jeff Jones | $125 | $105.48 | -1.3% | Aug 5, 2026 |
| Deutsche Bank | David Hoang | $120 | $105.25 | -5.2% | Jul 30, 2026 |
| Guggenheim | Analyst unavailable | $135 | $110.05 | +6.6% | Jul 28, 2026 |
| Mizuho Securities | Joseph Catanzaro | $140 | $114.12 | +10.6% | Jul 16, 2026 |
| RBC Capital | Brian Abrahams | $115 | $119.35 | -9.2% | Jul 13, 2026 |
| Truist Financial | Srikripa Devarakonda | $136 | $108.12 | +7.4% | Jun 29, 2026 |
| Canaccord Genuity | Edward Nash | $129 | $116.46 | +1.9% | Jun 26, 2026 |
| B.Riley Financial | Kalpit Patel | $155 | $116.46 | +22.4% | Jun 26, 2026 |
| Loop Capital Markets | Leah Rush Cann | $97 | $73.95 | -23.4% | Jun 8, 2026 |
| Canaccord Genuity | Edward Nash | $106 | $82.71 | -16.3% | May 6, 2026 |
| Morgan Stanley | Judah Frommer | $119 | $80.73 | -6.0% | Apr 30, 2026 |
| Morgan Stanley | Judah Frommer | $123 | $95.03 | -2.9% | Feb 26, 2026 |
| RBC Capital | Brian Abrahams | $108 | $91.87 | -14.7% | Feb 26, 2026 |
| Barclays | Eliana Merle | $133 | $72.15 | +5.0% | Jan 27, 2026 |
| RBC Capital | Analyst unavailable | $103 | $85.62 | -18.7% | Dec 16, 2025 |
| Stephens | Sudan Loganathan | $110 | $89.9 | -13.1% | Dec 11, 2025 |
| Mizuho Securities | Analyst unavailable | $120 | $89.9 | -5.2% | Dec 11, 2025 |
| Jefferies | Analyst unavailable | $122 | $86.82 | -3.7% | Dec 9, 2025 |
| Truist Financial | Srikripa Devarakonda | $116 | $86.27 | -8.4% | Dec 9, 2025 |
| H.C. Wainwright | Andrew Fein | $134 | $86.87 | +5.8% | Dec 9, 2025 |
| Oppenheimer | Analyst unavailable | $120 | $85.6 | -5.2% | Dec 9, 2025 |
| Morgan Stanley | Analyst unavailable | $127 | $87.21 | +0.3% | Dec 9, 2025 |
| Piper Sandler | Analyst unavailable | $125 | $94.3 | -1.3% | Dec 9, 2025 |
| Wells Fargo | Derek Archila | $116 | $94.3 | -8.4% | Dec 9, 2025 |
| Barclays | Analyst unavailable | $119 | $94.3 | -6.0% | Dec 9, 2025 |
| Leerink Partners | Analyst unavailable | $118 | $94.3 | -6.8% | Dec 8, 2025 |
| BTIG | Jeet Mukherjee | $138 | $94.3 | +9.0% | Dec 8, 2025 |
| Stifel Nicolaus | Alex Thompson | $114 | $93.76 | -10.0% | Dec 8, 2025 |
| Truist Financial | Analyst unavailable | $80 | $67.3 | -36.8% | Nov 26, 2025 |
| UBS | Analyst unavailable | $90 | $66.04 | -28.9% | Nov 26, 2025 |
| H.C. Wainwright | Analyst unavailable | $84 | $59.91 | -33.7% | Nov 5, 2025 |
| Barclays | Analyst unavailable | $70 | $59.91 | -44.7% | Nov 5, 2025 |
| Morgan Stanley | Analyst unavailable | $73 | $59.91 | -42.4% | Nov 4, 2025 |
| Jefferies | Analyst unavailable | $73 | $61.06 | -42.4% | Nov 4, 2025 |
| Oppenheimer | Jeff Jones | $67 | $59.91 | -47.1% | Nov 4, 2025 |
| Guggenheim | Brad Canino | $90 | $61.84 | -28.9% | Nov 3, 2025 |
| BTIG | Jeet Mukherjee | $75 | $58.32 | -40.8% | Oct 22, 2025 |
| Oppenheimer | Analyst unavailable | $63 | $56.6 | -50.2% | Oct 1, 2025 |
| Truist Financial | Analyst unavailable | $68 | $58.93 | -46.3% | Sep 30, 2025 |
| H.C. Wainwright | Analyst unavailable | $70 | $50.87 | -44.7% | Sep 18, 2025 |
| Barclays | Analyst unavailable | $60 | $48.78 | -52.6% | Sep 16, 2025 |
| RBC Capital | Brian Abrahams | $70 | $48.26 | -44.7% | Sep 16, 2025 |
| Oppenheimer | Jeff Jones | $53 | $44.12 | -58.1% | Jun 27, 2025 |
| BTIG | Jeet Mukherjee | $59 | $46.47 | -53.4% | Jun 26, 2025 |
| Jefferies | Kelly Shi | $64 | $46.21 | -49.5% | Jun 25, 2025 |
| Guggenheim | Michael Schmidt | $60 | $43.58 | -52.6% | Jun 3, 2025 |
| H.C. Wainwright | Analyst unavailable | $54 | $31.35 | -57.4% | Feb 28, 2025 |
| BMO Capital | Etzer Darout | $55 | $44.08 | -56.6% | Dec 5, 2024 |
| Wells Fargo | Derek Archila | $57 | $48.54 | -55.0% | Dec 2, 2024 |
| Oppenheimer | Jeff Jones | $56 | $49.47 | -55.8% | Sep 27, 2024 |
| Wolfe Research | Andy Chen | $65 | $47.78 | -48.7% | Aug 26, 2024 |
| H.C. Wainwright | Andrew Fein | $60 | $40.31 | -52.6% | Aug 8, 2024 |
| H.C. Wainwright | Andrew Fein | $46 | $32.29 | -63.7% | Jun 17, 2024 |
| Piper Sandler | Edward Tenthoff | $56 | $34.84 | -55.8% | May 23, 2024 |
| Oppenheimer | Jeff Jones | $52 | $36.3 | -58.9% | May 3, 2024 |
| Wells Fargo | Analyst unavailable | $42 | $24.71 | -66.8% | Jan 3, 2023 |
| Morgan Stanley | Analyst unavailable | $41 | $27.05 | -67.6% | Dec 19, 2022 |
| Goldman Sachs | Analyst unavailable | $52 | $28.26 | -58.9% | Dec 16, 2022 |
| Leerink Partners | Analyst unavailable | $31 | $29.62 | -75.5% | Dec 15, 2022 |
| Morgan Stanley | Michael Turits | $45.2 | $29.11 | -64.3% | Dec 6, 2022 |
| Credit Suisse | Richard Law | $32 | $29.11 | -74.7% | Dec 6, 2022 |
| Morgan Stanley | Analyst unavailable | $37 | $31.81 | -70.8% | Aug 29, 2022 |
| Credit Suisse | Analyst unavailable | $61 | $32.83 | -51.8% | Aug 10, 2022 |
| Morgan Stanley | Analyst unavailable | $35 | $21 | -72.4% | May 4, 2022 |
| Credit Suisse | Analyst unavailable | $60 | $21.26 | -52.6% | May 4, 2022 |
| UBS | Eliana Merle | $80 | $43.2 | -36.8% | May 20, 2021 |
Track every rating change on KYMR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationKymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Historical context
All KYMR earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the KYMR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-02T11:00:45.503899+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-02T11:00:45.501143+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-02. For educational purposes only; not investment advice.